Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | LAP3 | P28838 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600361 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL14066236 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL366832 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL6012976 | 0.94 | ALDH1A1 (0.55) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL8426058 | 0.94 | ALDH1A1 (0.55) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| Benzyl Alcohol SCHEMBL27898646 | 0.92 | ALDH1A1 (0.53) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL8424336 | 0.91 | ALDH1A1 (0.56) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL8424338 | 0.91 | ALDH1A1 (0.56) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL15449774 | 0.91 | ALDH1A1 (0.61) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL19853604 | 0.91 | ALDH1A1 (0.52) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114082312-B | Hollow fiber membrane with chiral selectivity and method for separating metoprolol enantiomer by using same | 广州白云山汉方现代药业有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-114082312-A | Hollow fiber membrane with chiral selectivity and method for separating metoprolol enantiomer by using same | 广州白云山汉方现代药业有限公司 | 2022-02-25 | — | — | CN | claimed |
| CN-118879801-A | Left Carniy Synthesis process of statin | 山东玉满坤生物科技有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-114082312-B | Hollow fiber membrane with chiral selectivity and method for separating metoprolol enantiomer by using same | 广州白云山汉方现代药业有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-114621126-B | Improved ezetimibe preparation method | 重庆圣华曦药业股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-114621126-A | Improved preparation method of ezetimibe | 重庆圣华曦药业股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114082312-A | Hollow fiber membrane with chiral selectivity and method for separating metoprolol enantiomer by using same | 广州白云山汉方现代药业有限公司 | 2022-02-25 | — | — | CN | disclosed |
| EP-2861558-B1 | MACROMOLECULES FOR TREATING ATHEROSCLEROSIS | UNIV RUTGERS (US) | 2017-01-18 | — | — | EP | disclosed |
| US-9434681-B2 | Macromolecules for treating atherosclerosis | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434681-B2 | Macromolecules for treating atherosclerosis | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-09-06 | — | — | US | disclosed |
| US-20150175528-A1 | MACROMOLECULES FOR TREATING ATHEROSCLEROSIS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175528-A1 | MACROMOLECULES FOR TREATING ATHEROSCLEROSIS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2015-06-25 | — | — | US | disclosed |
| WO-2013188882-A1 | MACROMOLECULES FOR TREATING ATHEROSCLEROSIS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-12-19 | — | — | WO | disclosed |
| JP-2004300070-A | ACETAL ADDUCT OF MUSCONE, METHOD FOR PREPARING THE ADDUCT, AND METHOD FOR OPTICAL RESOLUTION OF (±)-MUSCONE | KAWAGUCHI YAKUHIN KK | 2004-10-28 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175528-A1 | MACROMOLECULES FOR TREATING ATHEROSCLEROSIS | APOB, MSR1, APOL1 | ALDH1A1 3245/4885TDP1 2465/4885MAPK1 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.